De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ChemoMetec Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Martin Behrens

Algemeen directeur

DKK 2.9m

Totale compensatie

Percentage CEO-salaris	30.0%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Jul 29

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Jul 29

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 08

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Dec 21

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Nov 15

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 17

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Sep 15

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

Jun 20

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Jun 01

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Jan 24

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Oct 26

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Oct 05

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Jul 18

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

Mar 27

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Dec 12

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

Aug 29

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

Apr 28

ChemoMetec A/S' (CPH:CHEMM) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 18

ChemoMetec (CPH:CHEMM) Is Growing Earnings But Are They A Good Guide?

Feb 10

What Type Of Shareholders Make Up ChemoMetec A/S' (CPH:CHEMM) Share Registry?

Jan 15

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Dec 20

Analyse CEO-vergoeding

Hoe is Martin Behrens's beloning veranderd ten opzichte van ChemoMetec's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	DKK 3m	DKK 877k	DKK 136m

Compensatie versus markt: De totale vergoeding ($USD 433.75K ) Martin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 1.76M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Martin te vergelijken met de prestaties van het bedrijf.

CEO

Martin Behrens (32 yo)

less than a year

Tenure

DKK 2,923,041

Compensatie

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Martin Behrens	CEO & COO	less than a year	DKK 2.92m	geen gegevens
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.27% DKK 20.8m
Kim Nicolajsen	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Christopher Runchel	Chief Sales Officer	no data	geen gegevens	geen gegevens
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	geen gegevens	geen gegevens
Lisbet Helles	Head of Marketing	less than a year	geen gegevens	geen gegevens
Søren Kjærulff	Head of R&D	no data	geen gegevens	geen gegevens
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CHEMM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.27% DKK 20.8m
Peter Reich	Independent Director	10yrs	DKK 100.00k	0.0083% DKK 637.8k
Kristine Faerch	Independent Director	4yrs	DKK 100.00k	0.00032% DKK 24.5k
Niels Thestrup	Chairman	3yrs	DKK 360.00k	0.011% DKK 857.6k
Betina Hagerup	Independent Director	3yrs	DKK 100.00k	0.0017% DKK 128.6k

3.5yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CHEMM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

ChemoMetec Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

Recent updates

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S Approves Dividend

Upcoming dividend of kr.4.00 per share

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Dividend of kr.4.00 announced

Price target increased by 8.0% to kr.473

Full year 2024 earnings: EPS exceeds analyst expectations

ChemoMetec A/S provides earnings guidance for the year 2024/25

Investor sentiment improves as stock rises 17%

ChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Investor sentiment improves as stock rises 15%

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

Investor sentiment improves as stock rises 17%

Now 20% overvalued

Price target increased by 14% to kr.513

Now 21% overvalued

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

Investor sentiment deteriorates as stock falls 18%

Investor sentiment deteriorates as stock falls 16%

ChemoMetec A/S Announces CEO Changes

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Investor sentiment improves as stock rises 30%

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First half 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

Price target decreased by 18% to kr.448

ChemoMetec A/S Announces Executive Changes

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Investor sentiment improves as stock rises 30%

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment improves as stock rises 17%

Upcoming dividend of kr.6.00 per share at 1.8% yield

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

Investor sentiment deteriorates as stock falls 20%

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Upcoming dividend of kr.4.00 per share